RecruitingPhase 2Phase 3NCT06785298

Fexofenadine as Adjuvant Therapy in Parkinson Disease

Clinical Study to Evaluate the Possible Efficacy and Safety of Fexofenadine in Patients With Parkinson's Disease Treated With Conventional Treatment

Sponsor

Tanta University

Enrollment

46 participants

Start Date

Dec 10, 2024

Study Type

INTERVENTIONAL

Conditions

Parkinson Disease

Summary

Parkinson's disease (PD) is a chronic, progressive neurological disorder characterized by both motor and non-motor symptoms. PD is the second most common neurodegenerative disorder after Alzheimer's disease and the most common movement disorder. PD has age-related pathology; it is present in 1-2% of the population over 60 years of age. The disease is characterized by a triad of disordered voluntary motor activity in the form of bradykinesia (slowness of movement) or even akinesia (absence of movement),rigidity and postural instability, and a resting tremor of the hands and less commonly the feet.

Eligibility

Min Age: 50 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether fexofenadine — an antihistamine commonly used for allergies — can help improve symptoms in people with Parkinson's disease when added to their existing dopamine medications. Researchers believe it may have a protective or symptom-relieving effect. **You may be eligible if...** - You are 50 years or older (male or female) - You have been diagnosed with Parkinson's disease - You are already on dopamine replacement therapy - Your Parkinson's is at a mild to moderately advanced stage (Hoehn and Yahr Stage 1-4) **You may NOT be eligible if...** - You have a different form of parkinsonism (such as drug-induced or atypical) - You are pregnant, breastfeeding, or planning a pregnancy - You have significant liver or kidney problems - You have active heart disease or are a substance abuser - You are allergic to the study medication Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLevodopa/carbidopa

A dopamine precursor, was first developed for the treatment of PD in the 1960s and continues to be the most-effective therapeutic agent for PD

DRUGFexofenadine

Fexofenadine is a second-generation antihistamine that does not penetrate the CNS and has the least CNS side effects among the second-generation antihistamines